Navigation Links
Aptuit Completes Sale of CTS to Catalent; Reinforces Commitment to Scientific Excellence and Most Comprehensive Early to Mid-Phase Development Capability
Date:2/17/2012

GREENWICH, Conn., Feb. 17, 2012 /PRNewswire/ -- Aptuit announces the completion of the sale of the Clinical Trials Supply business to Catalent Pharma Solutions on February 17, 2012.  Timothy C. Tyson, Chairman and CEO of Aptuit, LLC stated that Aptuit will continue to deliver scientific and service excellence to provide integrated capabilities for the early to mid phase drug development markets.

(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )

Mr. Tyson explained, "We have assembled a team comprised of some of the foremost scientific professionals in the industry. As part of our ongoing mission to engineer a better drug development process, we previously implemented a service performance initiative that drives every level of our organization. Today, Aptuit people are joining their 'heads for science' and their 'hearts for service' to continue to provide scientific excellence and a level of service that goes above and beyond what has come to be the industry standard."

Early to mid-phase services
Aptuit's early to mid-phase development services include Drug Design and Discovery, Solid State Chemistry, Preclinical Biosciences, API Development and Manufacture, Solid, Oral and Sterile Dosage Formulation, Clinical Sciences, Consulting Services and Aptuit INDiGO™, our proprietary program for fast track IND submission. Mr. Tyson noted Aptuit's best in class position in several of these key development areas, specifically citing the company's solid state chemistry, high potency API, accelerated development and lead optimization capabilities. 

Integrated or stand alone services
Stuart E. Needleman, President, Aptuit Scientific Operations, stressed that Aptuit has a team of scientific professionals in place who speak the client's language. He explained that they have extensive experience in working with multinational clients and emerging biotechs, and a track record for delivering on time and in full. "We thoroughly understand that business goals and scientific objectives vary greatly from client to client. That's why we are flexible in offering our clients an Integrated Service Package, consisting of all-inclusive early to mid-phase development services from a single Aptuit location, or stand alone services that are tailored to precisely meet their unique requirements," said Mr. Needleman.

The global scientific team led by a new CSO
The appointment of a Chief Scientific Officer (CSO) was cited as an example of the company's focus on scientific excellence. Mr. Needleman said, "The recent appointment of Dr. Jan-Olav Henck, a world renowned solid state chemist with significant industry experience, is another indication of how Aptuit customers benefit from the leadership and collaboration of some of the industry's most distinguished and experienced scientific minds." He further explained that while Aptuit scientists offer drug development expertise across all therapeutic areas, the company includes technical teams of scientific medical specialists who are focused on diseases and therapies that drive the current market, including neuroscience, cardiovascular, oncology and infectious disease.

In discussing Aptuit's strategically positioned global resources, Mr. Needleman cited Aptuit's world class drug design and optimization facility in Verona, Italy. "While the special strengths of some of our individual global facilities such as Verona are a decided advantage, we are a capability-centric organization: we focus on our client's needs," said Mr. Needleman. He added that all sites adhere to the same high quality standards of regulatory compliance.

In conclusion, Mr. Tyson said, "Aptuit continues to be a world-leading pharmaceutical services company, well-positioned for the dynamic growth projected in this market.  We plan to invest for growth, continue our passion for scientific excellence and deliver on exceptional customer service."

For more information, please contact Maria Garvey, Delfino Marketing at 914-747-1400 or maria@delfino.com or Paul Delfino at 914-494-4679 or email him at paul@delfino.com.

Aptuit is a global pharmaceutical services company focusing on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit's employees deliver an integrated suite of product development services to more than 800 companies worldwide driven by a deep commitment to client service, quality and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. For more information about Aptuit, visit www.aptuit.com

Aptuit: engineering a better drug development process through scientific excellence


'/>"/>
SOURCE Aptuit
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
2. Hill-Rom Completes Acquisition of Volker
3. Positron Completes Agreement With Institute of Nuclear Research, Troitsk, Russia for Additional Strontium-82 Supply
4. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
5. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
6. Sigma-Aldrich Completes Acquisition of BioReliance
7. China Nuvo Solar Energy, Inc. Completes Name Change to SurgLine International, Inc.
8. Enlivex Completes Patient Enrollment in its Phase I/II Clinical Trial
9. ULURU Inc. Completes Altrazeal® License Agreement for Europe
10. FDA Completes Work on Three Drug User Fee Programs
11. Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... responds to and which He does not. Yisrayl says with so many titles and ... true name, but he says with a little Scripture, backed with a lot of research, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Rob Lowe is ... now he has leant his presence to an educational purpose as the host of ... important one being cancer. In a recent episode, the series focuses on thyroid cancer. ...
Breaking Medicine News(10 mins):